Login
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc.

inhibikase.com

What Do They Do?

Develops an oral drug candidate intended to treat pulmonary arterial hypertension for people with the disease.

How Do They Make Money?

Under its license to ABLi for risvodetinib, Inhibikase may receive development and regulatory milestone payments, plus royalties based on net sales.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $48.3M in FY2025.

Operating income, FY2025
−1399% of revenue
▼ −82% (Loss) vs FY2024 (−$28.6M, −2674%)
Net income, FY2025
−1299% of revenue
▼ −75% (Loss) vs FY2024 (−$27.5M, −2574%)
Free cash flow, FY2025
−748% of revenue
▼ −45% (Loss) vs FY2024 (−$19.1M, −1791%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −72% (Loss)
vs −$11.9M in Q3 FY2025
  • Aug 21, 2026 Replaced its independent auditor CohnReznick was dismissed and Deloitte was appointed as the independent auditor for the next fiscal year.

Growing. Revenue grew 20% in 4 years, from $3.1M in FY2021 to $3.7M in FY2025, about 5% a year.

Shift in therapeutic focus The older report described a Parkinson's-focused pipeline and an imatinib prodrug program for chronic myeloid leukemia; the latest report centers on an imatinib prodrug for pulmonary arterial hypertension.

Risvodetinib licensing The older report described its Parkinson's drug program as company-developed; the latest report says risvodetinib development is paused and the drug has been licensed to ABLi for global development and commercialization.

Who Do They Compete With?

Competes with GlaxoSmithKline, Johnson and Johnson, United Therapeutics, Bayer Pharmaceuticals, Liquidia, Gilead Sciences, Merck and, Regeneron, Novartis Pharmaceuticals, Pfizer, Gossamer Bio, and Insmed

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support